PARP INHIBITOR BIOMARKERS MARKET ANALYSIS

PARP Inhibitor Biomarkers Market, by Product & Services (Product Type (Kits and Assays) and Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing and Others)), by Application (Breast Cancer, Ovarian Cancer, and Others (Prostate, Pancreatic, etc.) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023
Code : CMI3762
Pages :176
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Leading Companies

Global PARP Inhibitor Biomarkers Market – Key Players

Major players operating in the global PARP Inhibitor Biomarkers market include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc. Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Exagen Inc.,Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB and Thermo Fisher Scientific Inc.

Global PARP Inhibitor Biomarkers Market Cross Sectional Analysis:

Key players are making PARP Inhibitor Biomarkers with advance technology emerging economies is also expected to boost demand PARP Inhibitor Biomarkers market in North America region. For instance, in October 2020, Myriad Genetic Laboratories, Inc., a genetic testing and precision medicine company based in Salt Lake City, Utah, U.S., introduced Myriad's BRAC Analysis Treatment method from the Japanese Ministry of Health, Labor, and Welfare to be utilized as a partnered treatment with the PARP constraints.